Product news

Share this article:
Canadian regulators have approved Novartis' Diovan (valsartan) to treat chronic heart failure in patients who cannot tolerate angiotensin-converting-enzyme (ACE)  inhibitors, a common type of heart failure therapy.   
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION